WC
VRTX icon

Waterloo Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Waterloo Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37M Sell
3,068
-861
-22% -$401K 0.1% 181
2025
Q4 		$1.78M Buy
+3,929
New +$1.69M 0.13% 154
2025
Q2 		– Sell
-753
Closed -$365K – 488
2025
Q1 		$365K Buy
+753
New +$351K 0.03% 295
2024
Q3 		– Sell
-752
Closed -$352K – 398
2024
Q2 		$352K Buy
+752
New +$326K 0.04% 269

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Waterloo Capital's VRTX Position: Q1 2026 in Review

Waterloo Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q1 2026, selling an estimated $401K and leaving 3,068 shares worth $1.37M. The position accounts for 0.1% of the portfolio, ranked #181.

Waterloo Capital first reported a position in VRTX in Q2 2024 and has held it in 4 quarters since. The position peaked at $1.78M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Waterloo Capital held 3,068 shares of Vertex Pharmaceuticals worth $1.37M as of Q1 2026.
  • Waterloo Capital sold 861 Vertex Pharmaceuticals shares in Q1 2026, an estimated $401K.
  • Vertex Pharmaceuticals made up 0.1% of Waterloo Capital's portfolio in Q1 2026, its #181 holding.
  • Waterloo Capital first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 4 quarters since.
  • Waterloo Capital's Vertex Pharmaceuticals position peaked at $1.78M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Waterloo Capital's 13F filing for Q1 2026, filed 12 May 2026.